News on cancer research & diagnostics, liquid biopsy, and cancer risk testing.
The Belgian company recently received €3.6 million to develop the signature into a clinical test within the next three years.
Investigators will use Biocept's liquid biopsy tests to detect ALK rearrangements both at baseline and to monitor treatment response and resistance mechanisms.
The study, launched today, aims to evaluate the use of liquid biopsy and natural killer cell testing for the early detection of recurrent breast cancer.
The firm is looking for outside partners to tackle test commercialization as it begins to bring its second-generation colorectal cancer assay to market.
The company expects the new trials to start this fall, and plans to submit to the FDA next year to get the agency's stamp of approval.
